Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico

BACKGROUND. NVX-CoV2373, an adjuvanted, recombinant SARS-CoV-2 spike (rS) protein vaccine, consistently demonstrated protective efficacy against COVID-19 in clinical trials and has received regulatory authorizations or approvals worldwide. METHODS. PREVENT-19 (NCT04611802) is a phase 3, randomized,...

Descripción completa

Detalles Bibliográficos
Autores principales: Áñez, Germán, Kotloff, Karen L., Gay, Cynthia L., Nelson, Joy, Dunbar, Haoua, Cloney-Clark, Shane, McGarry, Alice, Woo, Wayne, Cho, Iksung, Plested, Joyce S., Glenn, Gregory M., Dunkle, Lisa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197803/
https://www.ncbi.nlm.nih.gov/pubmed/37214968
http://dx.doi.org/10.1101/2023.05.08.23289670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197803/
https://www.ncbi.nlm.nih.gov/pubmed/37214968
http://dx.doi.org/10.1101/2023.05.08.23289670

Ejemplares similares